Note: This section contains information in English only.The US approval of Mylan NV's MS treatment Copaxone, generic version of Teva's blockbuster, drove shares of the drugmaker up 19%, affecting rival's shares.
Wed, 04 Oct 2017 20:06:49 GMT
Source: Dukascopy Bank SA